Latest News

  • Follow the Money: Cancer Early Detection Tests, Advancing Self-Sampling Solutions Expansion, Circular RNA-Based Clinical Assay

    Diagnostics World | Freenome will advance the pipeline of single-cancer and tailored multi-cancer early detection tests built on its multiomics platform; Capitainer will continue its journey toward becoming the foremost provider of self-sampling solutions with new funding; Circular Genomics plans to build and scale commercial operations in preparation for the launch of the world's first circular RNA-based clinical assay; and more.

    Feb 28, 2024
  • Ultima’s Silicon Wafer Sequencing Launches on $100 Genome, Part Per Million Accuracy

    Diagnostics World | Among the sequencing news at AGBT earlier this month, Ultima Genomics announced the commercial launch of its UG 100 ultra-high throughput sequencing platform.

    Feb 27, 2024
  • Universal Newborn Screening for Congenital CMV Would Have a Significant Impact

    Diagnostics World | It is time for clinical laboratories to push for cytomegalovirus (CMV) testing as part of the standard newborn screening process. We have seen some progress on this front recently, with Minnesota becoming the first state in the US to approve universal CMV screening at birth. However, Minnesota should not stand alone; newborns everywhere would benefit from CMV screening.

    Feb 23, 2024
  • Electronic White Blood Cell Tracker Developed For Near-Patient Testing

    Diagnostics World | A revolution is underway in the diagnostics world that is reminiscent of what transpired in the computing field before the advent of PCs and smartphones. The unimagined possibilities of today will come from democratizing technology so that instead of sending patients to the lab, the lab will get sent to patients—and, ultimately, be available to them in the form of at-home testing kits.

    Feb 21, 2024
  • Measuring Sleep Apnea Severity With Sweat

    Diagnostics World | Researchers in Spain are advocating the use of sweat in metabolomics studies to measure the severity of sleep apnea. It’s an ideal alternative to blood and urine because the sampling is noninvasive and accessible, and the biofluid doesn’t require much manipulation by the test operator that can introduce variability.

    Feb 20, 2024